| Ytd | -80.84% | |
| 1y | -80.54% |
| Open | 1.76 | Prev Close | 1.78 | Low | 1.72 | High | 1.81 | Mkt Cap | 115.94M |
| Vol | 359.13K | Avg Vol | 748.14K | EPS | -2.07 | P/E | N/A | Forward P/E | -3.53 |
| Beta | -0.76 | Short Ratio | 11.39 | Inst. Own | 83.23% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 09-08 | 50-d Avg | 1.85 | 200-d Avg | 4.95 | 1yr Est | 27.00 |
ENGN News
enGene Therapeutics Inc. (ENGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference
enGene Therapeutics remains deeply undervalued, trading below its $3.97/share cash position despite
Citizens analyst Silvan Turkcan reiterates enGene Therapeutics (NASDAQ:ENGN) from Market Perform
enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(0.47) per share which missed the analys
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company
enGene (NASDAQ: ENGN - Get Free Report) and Oncobiologics (NASDAQ: OTLK - Get Free Report) are both
enGene NASDAQ: ENGN outlined its view of the high-risk Bacillus Calmette-Guérin-unresponsive non-mus
enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Inv
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company
enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company
CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, a biotechnology company
Wall Street analysts updated ratings for CURB, INTU, ENGN. See their outlooks and targets at Benzing
Morgan Stanley analyst Judah Frommer downgrades enGene Therapeutics (NASDAQ:ENGN) from Equal-Weig
Top analysts changed ratings on top names, including Sunrun, enGene Therapeutics, Camp4 Therapeutics
HC Wainwright & Co. analyst Andres Y. Maldonado maintains enGene Therapeutics (NASDAQ:ENGN) w
Recent Corporate UpdatesReduction in Force and Executive Departures: In June 2026, enGene implemente
enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(0.43) per share which beat the analyst
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company
LOS ANGELES, June 11, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litiga
LOS ANGELES, June 8, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigat
enGene Therapeutics is rated Buy, trading below its $4.66/share cash floor despite weak Phase 2 data
NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves
LOS ANGELES--(BUSINESS WIRE)---- $ENGN--ENGN Investors Have Opportunity to Join enGene Therapeutics
NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
enGene stock sinks after Phase 2 bladder cancer trial shows durability concerns. Analysts slash pric
Citizens analyst Silvan Turkcan downgrades enGene Therapeutics (NASDAQ:ENGN) from Market Outperfo
Wells Fargo analyst Yanan Zhu downgrades enGene Therapeutics (NASDAQ:ENGN) from Overweight to Equ
HC Wainwright & Co. analyst Andres Y. Maldonado maintains enGene Therapeutics (NASDAQ:ENGN) w
Piper Sandler analyst Allison Bratzel downgrades enGene Therapeutics (NASDAQ:ENGN) from Overweigh
Dow falls over 100 points, S&P 500 and NASDAQ also down. Tech sector up, energy stocks down. US
US stocks higher Thursday morning, Dow down 0.28%, Nasdaq up 0.50%, S&P 500 up 0.07%. Tech secto
WBB Securities analyst Karen Sterling initiates coverage on enGene Therapeutics (NASDAQ:ENGN) wit
Name change reflects transition towards potential commercial organization in 2027Planned Biologics L
Oppenheimer analyst Leland Gershell maintains enGene Holdings (NASDAQ:ENGN) with a Outperform and
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates enGene Holdings (NASDAQ:ENGN) with
enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(0.44) per share which beat the analyst
Shares of AppLovin Corporation (NASDAQ: APP) rose sharply in today’s pre-market trading after the c
U.S. stock futures were higher this morning, with the Dow futures trading higher by around 70 points
Gainers Benson Hill, Inc. (NYSE: BHIL) shares jumped 48.1% to $0.3740.